the news now

The world's news, cross-checked among reputable sources.

This is a new development in a story we have covered before · earlier coverage

Anvisa Approves First Generic Semaglutide Weight Loss Pen in Brazil

2 sources · Brazil

Who reported this

  • UOL Brazil · Centre-left · Grupo Folha
  • CNN Brasil Brazil · Centre · Rubens Menin (MRV)

What the colours mean

  • Left
  • Centre-left
  • Centre
  • Centre-right
  • Right
  • A hatched block means the outlet is affiliated with, or controlled by, a state.

Political lean describes where an outlet sits within the politics of its own country. It is never a position on a single global scale.

Political lean is comparable inside one country and not across them, which is why the bar groups by country first. Publicly funded broadcasters are not marked as state-linked.

The owner of each outlet is listed as a matter of record, not as a judgement about the outlet.

Every source for this story reports from Brazil.

Brazil's health regulatory agency, Anvisa, has approved the first generic semaglutide pen for the treatment of type 2 diabetes. The generic medication is produced by the pharmaceutical company EMS. In addition to the generic version, Anvisa approved a similar medication from the laboratory Germed, which will be sold under the name Semaclique. Both products are injectable solutions administered weekly via pre-filled pens and must be stored in refrigerators between 2 and 8 degrees Celsius. As with all GLP-1 medications, these treatments require a medical prescription in two copies.

How each side framed it

Centre-left
The center-left outlet focused specifically on the approval of the generic version for the treatment of type 2 diabetes.
Centre
The center outlet focused on the broad availability of the medications, highlighting both the generic and the branded similar version.

Sources

100% of the statements in this article were traced back to the source articles listed above.